Go to contentGo to menuGo to searchGo to the news list

MitoVasc : physiopathologie cardiovasculaire et mitochondriale

Main navigation



    Cardioprotection in acute myocardial infarction

    Cardioprotection in acute myocardial infarction

    • Share this page on social networks
    • E-mail this page

      Send by mail

      Separated by coma
    • Print this page

    Fabrice Prunier



    Team members :


    Preclinical team :

    Fabrice Prunier, M.D. , Ph.D.,  PU-PH

    Sophie Tamareille, Ph.D.,  Engineer UA

    Aglae Herbreteau, Technician UA

    Louwana Allawa, Ph.D. student

    Xavier Dieux, Ph.D. student


    Clinical team:

    Fabrice Prunier, M.D. , Ph.D.,  PU-PH

    Alain Furber, M.D. , Ph.D.,  PU-PH

    Loic Bière, M.D. , Ph.D.,  MCU-PH

    Jérémy Rautureau, Clinical trial engineer

    Thiébaud Boucher, Clinical trial engineer


    Myocardial infarction is a leading cause of death worldwide.  Although prompt reperfusion is crucial to reduce the infarct size and improve survival, it can paradoxically induce injury itself, leading to functional and metabolic disruptions of the heart as well as morphological changes. Cardioprotective strategies are developed to reduce the impact of reperfusion injury in experimental models and in randomized clinical trials.


    Technical platform : Cardiac function in vivo, ex vivo, in vitro

    In vivo exploration
    • Echocardiography Doppler (Vivid 7, GE Healthcare)
    • Implantable telemetry ECG (DSI)
    • Hemodynamics (Millar pressure catheter)
    • Myocardial infarction models (mice and rats): myocardial ischemia/reperfusion, permanent coronary artery occlusion
    Ex vivo cardiac function:
    • Langendorff isolated perfused heart (mice and rats) with monitoring of hemodynamic parameters (EMKA Technologies, ADInstruments)
    In vitro:
    • Hypoxia/reoxygenation on isolated adult and neonatal cardiomyocytes (rat, mice) and H9C2 cell line